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Introduction: Aminoglycosides like streptomycin are well-known for binding at specific regions of 
ribosome RNA and then acting as translation inhibitors. Nowadays, several pathogens have been 
detected to acquire an undefined strategy involving mutation at non structural ribosome genes like 
those acting as RNA methylases. rsmG is one of those genes which encodes an AdoMet-dependent 
methyltransferase responsible for the synthesis of m7G527 in the 530 loop of bacterial 16S rRNA. This 
loop is universally conserved, plays a key role in ribosomal accuracy, and is a target for streptomycin 
binding. Loss of the m7G527 modification confers low-level streptomycin resistance and may affect 
ribosomal functioning.
Objectives: After taking into account genetic information indicating that some clinical isolates of human 
pathogens show streptomycin resistance associated with mutations at rsmG, we decided to explore 
new hot spots for mutation capable of impairing the RsmG in vivo function and of promoting low-level 
streptomycin resistance.
Materials and methods: To gain insights into the molecular and genetic mechanism of acquiring this 
aminoglycoside resistance phenotype and the emergence of high-level streptomycin resistance in rsmG 
mutants, we mutated Escherichia coli rsmG and also performed a genotyping study on rpsL from several 
isolates showing the ability to grow at higher streptomycin concentrations than parental strains.
Results: We found that the mutations at rpsL were preferentially present in these mutants, and we 
observed a clear synergy between rsmG and rpsL genes to induce streptomycin resistance.
Conclusion: We contribute to understand a common mechanism that is probably transferable to other 
ribosome RNA methylase genes responsible for modifications at central sites for ribosome function.
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Mutaciones en genes modificadores de ARN ribosómico y la resistencia a aminoglucósidos: el 
caso del gen rsmG
Introducción. Los aminoglucósidos son moléculas antibióticas capaces de inhibir la síntesis de proteínas 
bacterianas tras su unión al ribosoma procariota. La resistencia a aminoglucósidos está clásicamente 
asociada a mutaciones en genes estructurales del ribosoma bacteriano; sin embargo, varios estudios 
recientes han demostrado, de forma recurrente, la presencia de un nuevo mecanismo dependiente 
de mutación que no involucra genes estructurales. El gen rsmG es uno de ellos y se caracteriza por 
codificar una metiltransferasa que sintetiza el nucleósido m7G527 localizado en el loop 530 del ribosoma 
bacteriano, este último caracterizado como sitio preferencial al cual se une la estreptomicina. 
Objetivo. Partiendo de las recientes asociaciones clínicas entre las mutaciones en el gen rsmG y la 
resistencia a estreptomicina, este estudio se propuso la caracterización de nuevos puntos calientes de 
mutación en este gen que puedan causar resistencia a estreptomicina usando Escherichia coli como 
modelo de estudio. 
Materiales y métodos. Se indagó sobre el mecanismo genético y molecular por el cual se adquiere la 
resistencia a estreptomicina y su transición a la resistencia a altas dosis mediante mutagénesis dirigida 
del gen rsmG y genotipificación del gen rpsL. 
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Resultados. Se encontró que la mutación N39A en rsmG inactiva la proteína y se reportó un nuevo 
conjunto de mutaciones en rpsL que confieren resistencia a altas dosis de estreptomicina. 
Conclusiones.  Aunque los mecanismos genéticos subyacentes permanecen sin esclarecer, se concluyó 
que dichos patrones secuenciales de mutación podrían tener lugar en otros genes modificadores del 
ARN bacteriano debido a la conservación evolutiva y al papel crítico que juegan tales modificaciones 
en la síntesis de proteínas.
Palabras clave: ARN/biosíntesis, estreptomicina, metilación, K, aminoglucósidos, mutagénesis.
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Aminoglycosides are probably the most widely 
used group of broad-spectrum antibiotics to over-
come bacterial infections and to prevent pathogen 
dissemination. Despite their antimicrobial therapy 
potential, toxic effects and physiology dysfunctions 
are well-known in patients under long-lasting 
or recurrent aminoglycoside treatment (1,2). In 
biochemical terms, aminoglycosides are composed 
of modified sugar moieties where several amine 
groups are present to confer cationic properties 
to the molecule as a whole. Consequently, amino-
glycosides bind to certain RNA regions of prokaryotic 
ribosome RNA (rRNA) (3,4) and then they act as 
protein synthesis inhibitors. 
Nowadays, mutations at non structural ribosome 
genes frequently appear to confer aminoglycoside 
resistance, including the genes encoding the 
different AdoMet-dependent methylases respon-
sible for post-transcriptional modification of rRNAs. 
One of the classical and first reported cases is 
rsmA, where the presence of mutations inactivating 
the RsmA function allows kasugamycin resistance 
(5-10). RsmA is a well-studied dimethyltansferase 
enzyme which catalyzes the synthesis of the m62A 
ribonucleotide at positions 1618 and 1619 of 16S 
rRNA in E. coli. This family of proteins is widely 
distributed in all major kingdoms of life: Eukaryota, 
Archaea and Bacteria. Although methylations 
at rRNA are almost fully depicted, at least in 
Bacteria and Eukaryota cells, their evolutionary 
and functional meaning remain unclear. However, 
few studies have recently analyzed the role of 
methylations at 16S and 23S rRNA in maintaining 
ribosome accuracy, which is experimental evidence 
to support the function of rRNA methylations for 
the first time (11,12). 
Among aminoglycosides, streptomycin is probably 
the best known given its antibiotic effect in 
tuberculosis treatment in the late 1940’s. Strepto-
mycin binds to 16S rRNA in four different domains, 
one including nucleotides G526 and G527 in 
the 530 loop, thus perturbing the A-site function 
and leading to translational misreading (13,14). 
Classically, streptomycin resistance mutations have 
been preferentially associated with mutations in 16S 
rRNA (530 loop, and helix 44 proximity comprising 
the 1402-1410 and 1490-1498 positions) and S12 
protein (rpsL) (15-17). 
Interestingly, recent reports indicate that mutations 
in a specific rRNA methyltransferase gene confer 
streptomycin resistance (18,19). The gene involved 
in this resistance pattern is rsmG (previously 
known as gidB). rsmG encodes a Class-I and 
AdoMet-dependent RNA methyltransferase that 
specifically methylates the N7 position of the purine 
ring at G527 of 16S rRNA in E. coli. Loss of RsmG 
activity confers low-level streptomycin resistance 
and inexplicably prompts the appearance of high-
level streptomycin resistance mutations (18-22). 
We recently reported an extensive mutational 
analysis to address the hot spots of mutation within 
the rsmG gene to confer streptomycin resistance 
(23). Simultaneously, we presented evidence for 
the critical role of RsmG activity of a certain set 
of residues located at the catalytic and co-factor 
binding sites of the enzyme (23). 
The aim of this study was to explore the molecular 
genotype of the E. coli rsmG mutants explaining 
transition from low-level to high-level streptomycin 
resistance, and to present new hot spots of mutation 
to impair the RsmG function, all of which are likely 
genetic traits for screening in human pathogens and 
clinical isolates to explain potential streptomycin 
resistance phenotype.
Materials and methods
Bacterial strains, plasmids, and media
Escherichia coli rsmG and a parental wild-type 
strain were obtained from the National BioResource 
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Project (NIG, Japan). The pBAD-TOPO and 
pET15b plasmids were obtained from Invitrogen® 
and Novagen®, respectively. C-terminal Flag-
tagged rsmG was cloned into pBAD-TOPO using 
these respective forward and reverse primers: 
rsmG-flag-F 5’-GATACCATGGTGCTCAACAAAC
TCTCCTTACTGC and rsmG-flag-R 5’-TTATTAtttg
tcgtcgtcgtctttatagtcAATTTTATTTGCTTTAATCAC
CACC. C-terminal 6His-tagged rsmG was cloned 
into the pET15b plasmid using primers: rsmG-his-F 
5’-GATACCATGGTGCTCAACAAACTCTCCTTAC
TGC and rsmG-his-R 5’-AGATAGGATCCTTATTA
atgatggtgatgatggtgAATTTTATTTGCTTTAATCAC 
CACC, where the NcoI and BamHI restriction sites 
were encoded (sequences in bold). The sequence 
encoding respective tags are denoted by underlined 
lower case. LBT (Luria Bertani broth containing 40 
µg/ml thymine) and LAT (LBT containing 20 g of 
Difco agar per liter) were used for routine cultures 
and for the plating of E. coli. LBT or LAT media with 
20 µg/ml or 100 µg/ml of streptomycin (Sigma) were 
used to test low-level and high-level streptomycin 
resistance, respectively.
Sequence and comparative structural analysis
The phylogenetic distribution of RsmG was studied 
by downloading a set of 134 sequences, belonging 
to the major eubacterial groups, from the Uniprot 
database (24). They were aligned using the Probcons 
program with 1,000 refinement iterations (25). Then, 
a Hidden Markov Model (HMM)-based profile was 
built using the HMMER v 3.0 application and default 
parameters (26). A consensus sequence of the 
RsmG family was extracted and used for massive 
searching in a local bacteria genome database 
consisting in more than 1,200 non redundant 
complete genomes downloaded from the NCBI 
FTP site (ftp://ftp.ncbi.nih.gov/genomes/Bacteria/). 
A general procedure for detecting functional residues 
in protein families based on sequence analysis was 
used (27). The RsmG protein from Bacillus subtilis 
(Protein Data Bank – PDB - id 1XDZ) was used 
as a template to model the missing loops of the E. 
coli RsmG protein (28) (PDB id 1JSX). The E. coli 
RsmG sequence was submitted to the SwissModel 
server (29) to be modeled over the 1XDZ template. 
Then, the best model based on ANOLEA and 
QMEAN energy minimization was used as a 
template for the manual docking of the AdoMet 
co-factor using the RsmG protein from Thermus 
thermophilus (20) (PDB id 3G88). The alpha 
carbons of the glycines conforming the canonical 
AdoMet-binding motif 73GxGxG77 were used to 
superimpose both structures with DeepView (30). 
The RSM deviation between the AdoMet motifs was 
calculated to be 0.14 Å. Molecular graphics images 
were produced using the UCSF Chimera package 
from the Resource for Biocomputing, Visualization, 
and Informatics at the University of California, San 
Francisco, USA (31).
Protein techniques
Western blotting, in vivo complementation assays, 
AdoMet affinity and in vivo rRNA modification activity 
measuring of the RsmG wild-type and N39A mutant 
were performed as previously reported (23).
Emergence of spontaneous high-level 
streptomycin resistance and genotyping
The mutants exhibiting high-level streptomycin 
resistance were obtained from wild-type strains 
and their respective rsmG mutants. Serial dilutions 
of a defined cell suspension (5 ml) of each strain 
were spread on LAT plates containing 100 µg/
ml of streptomycin (Sigma). Serial dilutions of 
the cell suspension were also plated on LAT 
plates without streptomycin to determine the 
numbers of viable cells in the cell suspension. 
The colonies showing high-level streptomycin 
resistance were isolated and passed twice in 
LB media containing 100 µg/ml of streptomycin. 
The genomic DNA from those isolates with stable 
high-level streptomycin resistance was isolated 
using the DNA Isolation Kit for Cells and Tissues 
(Roche), and the rpsL gene was amplified by 
PCR using the Expand High Fidelity PCR System 
(Roche) and the following primers: rpsL-F 5’-
ACACCTTTTCGGCATCGCC and rpsL-R 5’-
CTACGAGTTTAGTTTGACATTTAAG to hybridize 
~100 nt upstream and downstream, respectively, 
of the rpsL coding region. Sanger sequencing 
from purified PCR was conducted using forward 
primer rpsL-F.
Results
Sequence analysis of the RsmG family of proteins
For the purpose of retrieving new residues that 
are critical for the RsmG function and the probable 
hot spot sites for mutation, an amino acid profile 
of the RsmG family of proteins was built from 
134 representative sequences of major bacterial 
groups (see Materials and methods). Then, new 
residues were selected as hot spots according 
to their localization in the three-dimensional 
structure (holoenzyme modelled for E. coli RsmG 
protein) and the information content inferred from 
the Hidden Markov Model (HMM) analysis of the 
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multiple sequence alignment (MSA), where those 
residues located close to the catalytic site of the 
enzyme were of interest. After discarding the 
previously characterized ones (23), we aimed to 
study a set of the residues lacking from available 
RsmG proteins structures (20,28) where some 
displayed high predominance (figure 1A). 
In the E.coli RsmG structure, the region comprising 
the amino acids from positions 36 to 47 was lacking. 
After loop modelling (see Materials and methods), 
this structural region was predicted to be located 
over the co-factor binding site (figure 1C), and N39 
was predicted as being a critical residue given the 
conservation pattern along the alignment and the 
disposition of its side chain facing the active site of 
protein. Therefore, experimental approaches were 
designed to test the functional relevance of N39 
in RsmG activity (see the next section). Moreover, 
we further analyzed the phylogenetic distribution 
of rsmG among bacterial species, as well as the 
occurrence profile of other RNA methyltransferases 
that modify E. coli 16S rRNA. This aim could provide 
information about its presence in bacterial genomes 
which could present or acquire streptomycin 
resistance features by the mutation of rsmG gene. 
We found that enzyme RsmG was encoded in most 
of the bacterial genomes analyzed (more than 
1,200) with very few exceptions (figure 1B). 
Accordingly, rsmG seems to play a critical role in 
the ribosome function of prokaryotes because its 
conservation pattern resembled those observed 
for RsmD, RsmH/RsmI, and RsmE, whose acting 
sites converged at the P site of the 30S ribosome 
subunit where codon-anticodon pairing occurs 
between the mRNA and aminoacylated-tRNA 
during elongation (32,33). Therefore, whereas the 
conserved methylations at positions G966, C1402, 
and 1498 have been demonstrated to be central 
for translation initiation (34,35), m7G527 could 
participate in tRNA selection in promoting the 
correct rotation of the 530 loop, thus maintaining 
the A-site proper function and avoiding translational 
misreading (13,14), hypothetical function that needs 
to be studied in deep given the growth phenotype 
of rsmG mutants (18).
Although only rsmG and rsmA, among the most 
conserved genes acting as RNA methylases of 16S 
rRNA, have been associated with aminoglycoside 
resistance, it would not be surprising to find 
aminoglycoside-resistant bacterial strains with point 
mutations of other very conserved genes such as 
rsmE, rsmI and rsmH, which act in the proximity of 
helix 44, a critical structure for translation initiation 
(36) and a selective site for aminoglycoside binding 
(37). In fact, recent reports have demonstrated 
that deletion of rsmF gene encoding the methylase 
acting on m5C1407 position of E. coli 16S rRNA, 
at helix 44 proximity, is also associated to low-
level aminoglycoside resistance (38). Despite 
its low conservation level (figure 1B), this data 
reinforces our hypothesis to acquire resistance 
through inactivation of housekeeping genes 
involved in rRNA methylation at selective sites for 
aminoglycoside binding. Consequently, all of them, 
and the remaining set of unknown genes encoding 
uncharacterized and species specific rRNA 
modifying genes, must be considered potential 
markers for aminoglycoside resistance screening.
Functional characterization of N39 from E. coli 
RsmG
The coding region of E. coli rsmG was cloned in 
vectors pBAD and pET15b to evaluate the role 
of N39 within the protein. The N39 residue was 
mutated to alanine in both constructs, and the ability 
to confer streptomycin resistance, to modify rRNA 
and to bind AdoMet were explored for this mutant 
and wild type proteins. After transforming the ∆rsmG 
cells with the pBAD plasmids encoding wild type 
and N39A versions of the C-terminal Flag-tagged 
RsmG protein, and being spotted on LB plates with 
a low streptomycin concentration (20 µg/mL), the 
cells carrying the N39A mutant of RsmG showed 
the original phenotype of the ∆rsmG cells, low-level 
streptomycin resistance (figure 1D), indicating that 
the N39A protein is inactive despite it being expre-
ssed (figure 1D). The activity of RsmG N39A in vivo 
was evaluated using the same growth conditions. 
As a result, the level of the 16S rRNA modification 
was studied by measuring the m7G nucleoside 
accumulated in the ∆rsmG cells harboring wild type 
and N39A versions of the RsmG-Flag encoded 
in pBAD plasmids. When comparing the amount 
of m7G detected by HPLC after the hydrolysis of 
16S rRNA from those strains expressing RsmG 
and the N39A mutant, we observed in the rsmG 
mutant carrying the N39A construct only a fraction 
of 0.24 ± 0.04 of m7G accumulated in the rsmG 
mutant carrying the plasmid-encoded wild type 
RsmG. This result indicates that mutation N39A 
largely affects the RsmG function, as previous 
inferred from the streptomycin resistance assay. 
To further explore whether the co-factor binding 
in RsmG is impaired with the N39A mutation, the 
Surface Plasmon Resonance (SPR) approach was 
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Figure 1. Sequence, structure and genomic analysis of E. coli RsmG methylase
A) Visualization of information content per position derived from multiple sequence alignment. The conserved residues at the missing 
loop and the AdoMet binding site in the 1JSX structure are depicted. A black-headed arrow show the N39 residue detected as a 
conserved trait in the RsmG family. Numbering the residues is done according to RsmG from E. coli. 
B) Phylogenetic distribution of rRNA 16S methylases in major eubacterial groups. 
C) Modeling the missing loop (positions 36 to 47) in E. coli RsmG. The amino acids comprising this modeled region are represented 
in a blue ribbon fashion. Atom representation is shown for residues N39, H53, D56, and R139, which seems to act in catalysis by the 
coordination of the 530 loop and/or the G527 target ribonucleotide. 
D) The low-level streptomycin resistance phenotype of the E. coli RsmG N39A mutant. Cell growth on LAT plates with 20mg/mL of 
streptomycin is shown in the respective expression pattern of the RsmG proteins.
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used to measure AdoMet affinity. AdoMet affinity 
assays were performed by over-expressing the 
C-terminal 6His-tagged RsmG proteins encoded in 
the pET15b plasmids from E. coli BL21 (DE3) cells. 
The RsmG wild-type protein showed an affinity of 
0.39 ± 0.02 µM by AdoMet, whereas the N39A 
mutant displayed a slight reduced (~3-fold) AdoMet 
affinity, being 1.19 ± 0.36 µM. 
When comparing with a previous analysis, this 
difference in AdoMet affinity is not expected to 
largely influence RsmG activity given that an RsmG 
mutant G75A, which directly affects the AdoMet 
binding site, presents an almost four-fold loss of 
affinity and maintains the RsmG protein active 
given both its phenotype in the streptomycin 
resistance assay and the in vivo activity of the 
protein (23). Therefore, we speculate that the N39 
residue could be involved in catalysis, maybe in 
helping to maintain the proper position of the 530 
loop and/or specifically the G527 ribonucleotide at 
the active enzyme site.
Characterization of ∆rsmG cells with high-level 
streptomycin resistance
To further study the genotype associated with 
the high-level streptomycin resistance of rsmG 
mutants (18), we performed a selection assay to 
recover the rsmG mutants that are able to grow 
at high streptomycin concentrations (100 µg/
mL). After this assay, we recovered 42-fold more 
emergence frequency of high-level streptomycin 
resistance in ∆rsmG cells than in the wild type 
ones. This inexplicably high frequency for the 
appearance of high-level streptomycin resistance 
cells has been previously identified in both E. coli 
and Mycobacterium tuberculosis and, in some 
cases, they involve mutations in the S12-encoding 
gene, rpsL (18). Consequently, we decided to 
analyze the rpsL genotype in these emerged high-
level streptomycin resistant isolates. A summary 
of this genotyping is shown in table 1. Globally, we 
found that 63% of these isolates had mutations 
in rpsL. In all, 16 point mutations were identified 
in 12 isolates, of which three showed double 
point mutations. The most frequent mutation 
was K88Q (7/16), reported to be found in high-
level streptomycin resistant isolates (39). Despite 
a previous study reporting no profound effects 
of the K88Q mutation in translation accuracy 
(40), the variation in K88 seems central for this 
spontaneous drug resistant phenotype of rsmG 
mutants given that two other type K88R mutations 
were found, evidencing that the mutations at 
the K88 codon covered more than 55% of the 
mutations reported for rpsL in this study. Notably, 
we present a new set of mutations that confer a 
high-level streptomycin resistance phenotype to 
rsmG mutants by involving the L7, K44, H77, and 
P91 residues of the S12 ribosome protein.
The transition/transversion ratio (R) observed 
(R = 0.397), which differed from the theoretical 
probability of occurrence (R = 0.5), together with 
the high prevalence of the rpsL mutations in 
combination with the rsmG mutation, support the 
notion of an obscure molecular strategy to promote 
streptomycin resistance and to evade drug therapy, 
as frequently found in clinical isolates; therefore, 
the complete understanding of these coupled 
mutations can help to design better strategies for 
microbial control and eradication.
Discussion
The present study aimed at shedding light on our 
understanding of new molecular mechanisms for 
aminoglycoside resistance. In addition to the large 
set of residues detected as hot spots of mutation 
Table 1. The rpsL genotyping of high-level streptomycin resistances
Isolate Mutation RpsL Codon change Mutation type
SR1
SR12
SR13
SR15
SR16
SR17
SR18
SR19
SR20
SR23
SR24
SR25
SR27
K44Q
K88Q
K88R
K88Q
K88Q
K88R
L7Q; K88Q
R86S; K88Q
R86C
K88Q
H77L; K88Q
P91S
H77L
AAA / CAA
AAA / CAA
AAA / AGA
AAA / CAA
AAA / CAA
AAA / AGA
CTG / CAG; AAA / CAA
CGT / AGT; AAA / CAA
CGT / TGT
AAA / CAA
CAC / CTC; AAA / CAA
CCG / TCG
CAC / CTC
Transversion
Transversion
Transition
Transversion
Transversion
Transition
Transversions
Transversions
Transition
Transversion
Transversions
Transition
Transversion
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in the E. coli rsmG gene (23), we present a new 
mutation in this gene, which largely impairs 
enzyme activity, and it could be useful to detect 
microorganisms with low-level streptomycin resis-
tance that are potentially able to develop high-
level resistance. Moreover, we present the partial 
genotyping of emerged high-level streptomycin 
resistant isolates by demonstrating a sequential 
mutation process to acquire such a phenotype. 
Mutations that confer a high-level streptomycin 
resistance phenotype to rsmG mutants preferentially 
appear on rpsL. We present a new set of mutations 
apart from K88Q which confer the ability to E. coli to 
grow in media at high streptomycin concentrations. 
Initial low-level aminoglycoside resistance steps, 
involving mutations at rRNA methylation genes, 
followed by the emergence of high-level resistant 
mutants, seems a common feature for this recently 
characterized treatment-evading strategy of micro-
bes and human pathogens (18,41). 
Therefore, we can expect a similar behavior and 
mutation-acquiring mechanisms for other genes 
acting at critical sites for the ribosome decoding 
function, like those methylating ribonucleotides in 
the proximity of helix 44. The step-by-step point 
mutation-acquiring process can indicate that cells 
would suffer loss of cell fitness in the very early 
selection process under antibiotic treatment, 
which would help evade the drug therapy, but 
would cause drastically reduced growth in a 
competitive environment. 
Nevertheless, fast adaptation mechanisms would be 
active in order to acquire compensatory mutations 
in specific genes, which would increase the level 
of antibiotic resistance in addition to attenuating 
the effect of the initial disadvantageous mutations. 
This likely short-term evolution mechanism for 
antibiotic resistance, based on the mutation of 
RNA methylation genes, must be studied in depth 
given that the complete understanding of this 
genetic response of pathogens against therapy 
could help us to design new strategies in order 
to avoid the emergence and dissemination of 
high-level aminoglycoside resistance. Indeed, 
this mechanism of mutation is not restricted to 
generate aminoglycoside resistance given that 
more recent reports have associated mutations at 
rRNA methylations genes with linezolid resistance 
in clinical isolates (42,43).
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